Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback